AccuVein Signs Exclusive Distribution Agreement with SinoPharma-UMD in China

AccuVein Inc., the global leader in vein visualization, announced today that they have signed an exclusive distribution agreement with SinoPharm-UMD to sell the award-winning AccuVein AV400 vein visualization device in China. The China Food and Drug Administration (CFDA) has recently approved the sale of the AccuVein AV400 in China.

“We are excited to announce SinoPharm as a key partner of AccuVein. SinoPharm has an established track record in providing high-quality medical products to hospitals and other healthcare providers in China, a country of 1.3 billion people”, said AccuVein Vice President, Jeff Schou. “AccuVein and SinoPharm together see this as a great opportunity to have a large scale impact on improving patient care and reducing healthcare costs in country.”

China as a matter of practice does more IVs than most other countries as they frequently deliver antibiotics intravenously. In 2009, for example, China consumed 10.4 billion bottles of IV fluid, equivalent to eight bottles per capita, an amount far in excess of the international average of 2.5 to 3.3 bottles per inhabitant. China’s market for medical devices is forecast to surpass the $55 billion mark this year, nearly double that of just two years ago.

The AccuVein AV400 vein visualization device can help reduce the need for multiple needle sticks, and ultimately improve patient care and satisfaction. A recent study showed a striking 45% reduction in escalation calls following the implementation of the AccuVein AV400, with 81% of nurses reporting an improved ability to cannulate veins. The Infusion Nurses Society in the U.S. is now recommending the use of vein visualization in their 2014 guidelines.

AccuVein’s vein illumination device is available for sale in over 120 countries worldwide. For the full list, please visit http://www.accuvein.com/how-to-buy/international/.

About AccuVein Inc.
AccuVein Inc. is the global leader in vein visualization technology. AccuVein’s flagship product, the AV400, is the world’s only hand-held, non-contact vein illumination solution. It allows healthcare professionals to see a map of peripheral veins on the skin’s surface with the goal of accessing or avoiding veins. It is built on proprietary technology as embodied in its growing patent portfolio that covers a broad range of imaging and medical diagnostic technologies.

About SinoPharm Group Co. Ltd.
In the 10 years since its establishment, the SinoPharm Group has developed into the largest distributor of pharmaceutical and healthcare products and a leading supply chain service provider in the People’s Republic of China. Sinopharm has a medical distribution network system of 30 distribution centers that meet international standards and nearly 2,000 retail outlets that cover 31 provinces, autonomous regions and municipalities in China. As a leading provider of supply chain services, it is China’s biggest retailer of medicine, healthcare products and medical equipment.

AccuVein, Inc.

AccuVein, Inc.
Medical imaging technology

Downloads

DownloadPress Release

Latest News

Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.

VitalConnect Announces Closure of $33m Series C Financing

VitalConnect, a leader in medical-grade wearable biosensor systems, has announced that it has closed a Series C Preferred Stock equity financing round of $33 million led by new investors MVM Life Science Partners and Baxter.

Providence Medical Technology announces new equity financing of $10.5 million

Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.

Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease

Wilson Therapeutics AB has announced that the Phase II study of WTX101 (bis-choline tetrathiomolybdate; Decuperate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint.

MVM invests €15.2m in Valneva SE

Valneva SE is a commercial stage vaccine company with products to prevent Japanese encephalitis and cholera